Company intelligence / Profile preview

NapaJen Pharma

Seattle, Washington, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

NJA-730, the lead program, is in clinical development for prevention of acute immune diseases (Graft vs Host Disease) associated with bone marrow transplants; other programs are in preclinical stages in immuno-oncology, vaccine adjuvants, and autoimmunity. No published clinical results yet.

Therapeutic areas: ImmunologyOncology
Modalities: OligonucleotideSmall interfering RNARNA therapy
Industry: Biotech

Drug pipeline

3 assets

Napa9-SPG

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Not specified in search results; company positions as a “partner-of-choice” for pharma/biotech seeking oligonucleotide drug delivery

Beyond the preview

Go deeper on NapaJen Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NapaJen Pharma.

Explore the full profile